Chief Executive Officer & Founder
Lisa has been a pioneer in the biotech/emerging pharmaceutical industry for 20 years. She is founder and CEO of Napo Pharmaceuticals, which brings proprietary products to the global marketplace through local partnerships. Napo embraces the “triple bottom line” goals of enhancing financial return by addressing global health needs in its development strategy and environmental sustainability in sourcing its lead product, which is harvested from rain forest areas.
Prior to founding Napo, she founded Shaman Pharmaceuticals, Inc., a natural product pharmaceutical company, in 1989. As CEO, she has raised >$250 million (including leading two IPOs). 1987 to 1989 Ms. Conte was a Vice President at Technology Funding, Inc., a venture capital firm. From 1985 to 1987 she conducted risk and strategy audits for start-up companies at Strategic Decisions Group. Lisa received her AB in Biochemistry from Dartmouth College, her MS in Physiology/Pharmacology from the University of California at San Diego and her MBA from the Amos Tuck School, Dartmouth College. She is the recipient of several entrepreneurship awards, including the 1994 E&Y Entrepreneur of the Year Award, has sat on several industry and academic boards, and was a nominee for the 2009 BIO Humanitarian Award.
Chief Financial Officer
Mr. Thompson joined Napo Pharmaceuticals as Vice President Finance and Chief Financial Officer in June 2002. From April 2001 to April 2002, he was the Chief Financial Officer of Celestry Design Technologies, Inc., a developer of design automation software. During his tenure at Celestry, that company grew from 70 employees to over 130 employees and established five offshore sales and R&D subsidiaries. Prior to Celestry, Mr. Thompson was in investment banking with Sutro & Co. Incorporated and Roth Capital Partners. Mr. Thompson holds a BBA in Finance from the University of Oklahoma and is a Certified Public Accountant.
Steven King, PhD
Executive Vice President of Sustainable Supply, Ethnobotanical Research & Intellectual Property
Dr. King has been an integral member of the Napo team since 2002 and prior to that, Dr. King served as the Vice President of Ethnobotany and Conservation at Shaman Pharmaceuticals, Inc. Dr. King has been recognized by the International Natural Products and Conservation Community for the creation and dissemination of research on the long-term sustainable harvest and management of Croton lechleri, the widespread source of crofelemer. Dr. King is currently a member of the board of directors of Healing Forest Conservatory, a California not-for-profit public benefit corporation. Dr. King holds a PhD in Biology from the Institute of Economic Botany of the New York Botanical Garden and an MS in Biology from the City University of New York.
Katie MacFarlane, PharmD
Senior Vice President, Commercial Development
Katie MacFarlane is an experienced pharmaceutical executive with over 25 years in the industry, including senior level roles in drug development, marketing, and sales management. Katie played a key role in the launch of many pharmaceutical brands, most notably Lipitor®, Celexa®, and Loestrin® 24. Katie’s GI experience includes clinical research in IBS (Librax®) and obesity (Xenical®), as well as consultation on Amitiza® (constipation and IBS) and crofelemer. Katie has held senior roles including Chief Commercial Officer of Agile Therapeutics, Vice President of Women’s Health and New Product Planning at Warner Chilcott, and Sr. Director of Marketing at Parke-Davis/Warner-Lambert.
Katie received her BS and PharmD degrees from Purdue University and completed a Postdoctoral Fellowship with Rutgers University and Hoffmann-LaRoche. She was named a Distinguished Alumna in 1999 and was awarded the Eaton Entrepreneur of the Year in 2012 by the Purdue University School of Pharmacy. Katie currently serves on the Purdue Pharmacy Dean’s Advisory Council, is a Founding Member and Advisor to IPhO, and serves as an Affiliate Faculty member in the Department of Pharmacy Practice at Purdue University. She is a member of the Board of Directors of RespireRx Pharmaceuticals and of INMED Partnerships for Children.
Brian Zorn, PharmD
Senior Vice President, Marketing & Sales
Brian Zorn has 23 years experience in pharmaceutical marketing, advertising, and sales. He held marketing resposibilities for key brands such as Accupril®, Omnicef®, Neurontin®, Bextra®, Menopur®, Euflexxa®, Endometrin®, PreCrea®, and PreLipid®. He was the General Manager at Trio Advertising, and at Parke-Davis, he was the Senior-Director of Marketing as well as a New Product Planner
Pravin Chaturvedi, PhD
Chair, Scientific Advisory Board
Dr. Chaturvedi is a serial entrepreneur and has founded or co-founded Scion, IndUS and Oceanyx Pharmaceuticals. He is a 25+ year drug development veteran in the pharmaceutical and biotech community. He is the President & Chief Executive Officer of Pivot Pharmaceuticals, Inc., which acquired IndUS Pharmaceuticals, a company founded by Dr. Chaturvedi. He serves as the Chair of the Scientific Advisory Board (SAB) for Napo Pharmaceuticals, where he previously served as the President and Chief Scientific Officer. Prior to his tenures at Pivot, IndUS, and Napo, he was the President and Chief Executive Officer of Boston-based Scion Pharmaceuticals, which was acquired by Wyeth (now Pfizer). Dr. Chaturvedi currently serves on the boards of Pivot, Oceanyx, Sindu Research Laboratories, Cellanyx, UBERDOC and FuelEd Schools. He has previously served on the boards of Scion Pharmaceuticals, Sindu Pharmaceuticals, Bach Pharma, PRADAN USA, and TiE Boston. He is also an adjunct faculty member at Georgetown Medical School and also serves on the advisory boards of several entities including Springboard Enterprises, a non-profit organization promoting women’s entrepreneurship.
Prior to his entrepreneurial journey, Dr. Chaturvedi spent several years at Vertex Pharmaceuticals as the Head of Lead Evaluation and was in the preclinical group at Alkermes. He started his career in the Product Development group at Parke-Davis/Warner-Lambert Company (now Pfizer). Dr. Chaturvedi holds a Ph.D. in Pharmaceutical Sciences from West Virginia University and has a bachelor’s degree from the University of Bombay.